Robert Michel
Until Robert L. Michel came along and founded The Dark Intelligence Group (DIG) two decades ago, the clinical laboratory industry and the anatomic pathology profession lacked a trustworthy source for information about the management and operations of medical laboratories. From its inception in 1995, The Dark Report quickly became the “go to” source of industry intelligence, innovations in lab management, and strategic market analysis.
This excellence in reporting has earned recognition from his peers. For example, twice Michel and The Dark Report have won national awards for best investigative reporting by the Specialty Information Publishers Association. In 2005, the award was for Michel’s coverage about how the anatomic pathology condominium laboratories (pod labs) operated by urologists and gastroenterologists came to be, who operated them, and how these owners marketed the AP condo labs to other physician groups. In 2009, Michel’s award for best investigative reporting resulted from his published interviews with Quest Diagnostics Incorporated when the company admitted that, for a period of 18 months, it had been reported inaccurate Vitamin 25(OH) D results because of problems with its laboratory-developed test methodology. The Dark Report’s story was picked up by The New York Times and was in the national news cycle for several days.
In his role as Editor-in-Chief, Michel brought unique capabilities to DIG and The Dark Report. His management training and diverse business experience—along with his skills as a concise writer and analyst—proved to be a winning combination for readers of The Dark Report. For that reason, Michel’s story has many intriguing elements.
Immediately prior to founding DIG, he had served in several executive positions for Nichols Institute based in Portland, Oregon, and San Juan Capistrano, California. This was during the time that Nichols Institute was an independent public lab company with annual revenues of about $280 million (prior to its acquisition by MetPath, Inc., now Quest Diagnostics Incorporated). He traveled extensively to many of the clinical lab business units owned by Nichols Institute in different regions of the United States and played a role in formulating effective market strategies in response to the emergence of closed-panel HMOs, capitated pricing, and full-risk managed care contracts, among other successful management initiatives.
Prior to his service at Nichols Institute, Michel served at three different Fortune 100 companies. These were Procter & Gamble, Centex Corporation, and Financial Corp. of America. Each was an opportunity to master new management techniques and apply them in different industries. Between these positions, he gained experience as an entrepreneur, having founded a real estate development firm and a general contracting company in the Southeastern United States.
Robert Michel earned a Bachelor of Arts degree in Economics at the University of California, Los Angeles, where he played rugby, a sport he participated in for another 22 years. He is a native of California and grew up in Santa Ana.
Articles by Robert Michel
LIS Market Will Change After Oracle and CliniSys Acquisitions
From the Volume XXIX, No. 2 – January 31, 2022 Issue
This is an excerpt of a 843-word article in the January 31, 2022 issue of THE DARK REPORT (TDR). The full article is available to members of The Dark Intelligence Group. CEO SUMMARY: The Oracle and CliniSys acquisitions will create major changes. With its purchase of Cerner Corpo…
LIS Market Will Change After Oracle, CliniSys Deals
From the Volume XXIX, No. 2 – January 31, 2022 Issue
CEO SUMMARY: With its purchase of Cerner Corporation, Oracle becomes the owner of Cerner’s Millennium laboratory information system (LIS) and CoPathPlus, Cerner’s anatomic pathology LIS. Only three weeks later, CliniSys, a division of Roper Technologies, announced it was acquiri…
Oracle’s $28b Cerner Deal Shows Value of Health Data
From the Volume XXIX, No. 2 – January 31, 2022 Issue
CEO SUMMARY: For three decades, pathologists and clinical lab executives regularly pointed out that clinical laboratory data was extremely valuable. But it seemed nothing changed, no one listened, and labs could not monetize their lab data. Now, one of Silicon Valley’s bigger play…
More LIS Consolidation as CliniSys Buys Horizon Lab
From the Volume XXIX, No. 2 – January 31, 2022 Issue
CEO SUMMARY: By acquiring Horizon Lab Systems, CliniSys has committed to moving some of its services beyond the clinical laboratory as Horizon sells into other lab markets, such as environmental management. Also, CliniSys will combine with Sunquest Information Systems,…
Non-COVID Part B Lab Spend Declined by 15.9% in 2020
From the Volume XXIX, No. 2 – January 31, 2022 Issue
MEDICARE PART B CLINICAL LABORATORY FEE SCHEDULE CUTS mandated by PAMA continue to bite deeply. A new government report shows that during fiscal 2020, the Medicare program spent 15.9% less for lab tests, when COVID-19 test payments are excluded. The fed…
Newsmaker Interview
From the Volume XXIX, No. 2 – January 31, 2022 Issue
Sonic Healthcare Acquires ProPath, PathGroup Buys Path Consultants
From the Volume XXIX, No. 2 – January 31, 2022 Issue
CONSOLIDATION AMONG PRIVATE PRACTICE ANATOMIC PATHOLOGY GROUPS continues with news that two large regional pathology groups decided to sell to larger pathology companies. The first transaction announced was on Dec. 16, 2021, when Sonic Healthcare …
Microbiome Startups Pushing into the Clinical Lab Space
From the Volume XXIX, No. 2 – January 31, 2022 Issue
REPUTABLE CLINICAL LABORATORY COMPANIES HAVE A NEW COMPETITOR in what has been called the Wild West of microbiome startups. Some of the companies in this nascent industry have been hailed for developing health breakthroughs while others have been indict…
Labs Can Team with Employers to Improve Worker Productivity
From the Volume XXIX, No. 2 – January 31, 2022 Issue
HEALTHCARE’S ONGOING TRANSFORMATION AND THE EMPHASIS ON VALUE-BASED REIMBURSEMENT are creating a new opportunity for savvy clinical laboratory executives and pathologists. This opportunity is centered around the need of self-insured employers to address the problem of employee presenteeism….
January 31, 2022 Intelligence: Late-Breaking Lab News
From the Volume XXIX, No. 2 – January 31, 2022 Issue
DNA-based breast cancer testing is taking a step forward. Illumina in San Diego, which sells next-generation sequencing (NGS) technology, announced a partnership with Agendia in Irvine, Calif., to develop in vitro diagnostic tests for oncology. Agendia offers proprietary breast …
CURRENT ISSUE

Volume XXXII, No. 13 – September 15, 2025
The Dark Report examines a new bill that would reform PAMA and avoid reimbursement rate cuts scheduled for January 2026. Clinical laboratory leaders are urged to make their voices heard in Congress. Also, an expert describes how labs can fix pre-analytical errors and avoid disaster.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized